American Research & Management Co. Has $9.90 Million Holdings in Johnson & Johnson (NYSE:JNJ)

American Research & Management Co. increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 76,553 shares of the company’s stock after buying an additional 905 shares during the quarter. Johnson & Johnson accounts for 3.0% of American Research & Management Co.’s investment portfolio, making the stock its 6th largest holding. American Research & Management Co.’s holdings in Johnson & Johnson were worth $9,904,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in JNJ. Zions Bancorporation N.A. grew its stake in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock worth $2,810,000 after acquiring an additional 73 shares during the period. Portland Global Advisors LLC grew its stake in shares of Johnson & Johnson by 0.9% during the 3rd quarter. Portland Global Advisors LLC now owns 8,744 shares of the company’s stock worth $1,131,000 after acquiring an additional 78 shares during the period. Vishria Bird Financial Group LLC grew its stake in shares of Johnson & Johnson by 3.0% during the 2nd quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock worth $381,000 after acquiring an additional 80 shares during the period. Alta Capital Management LLC grew its stake in shares of Johnson & Johnson by 3.9% during the 3rd quarter. Alta Capital Management LLC now owns 2,184 shares of the company’s stock worth $282,000 after acquiring an additional 82 shares during the period. Finally, G&S Capital LLC grew its stake in shares of Johnson & Johnson by 1.8% during the 3rd quarter. G&S Capital LLC now owns 4,668 shares of the company’s stock worth $604,000 after acquiring an additional 84 shares during the period. Institutional investors and hedge funds own 72.25% of the company’s stock.

Several research analysts have recently weighed in on JNJ shares. Atlantic Securities upgraded Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Bank of America reiterated a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price target for the company in a research note on Thursday, October 17th. Goldman Sachs Group set a $169.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Finally, Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $151.64.

Shares of JNJ opened at $133.00 on Friday. The stock’s 50-day simple moving average is $130.83 and its 200 day simple moving average is $134.05. The stock has a market capitalization of $343.25 billion, a price-to-earnings ratio of 16.26, a price-to-earnings-growth ratio of 2.20 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.00 by $0.12. The business had revenue of $20.73 billion for the quarter, compared to analysts’ expectations of $20.14 billion. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.05 EPS. On average, research analysts forecast that Johnson & Johnson will post 8.65 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $0.95 per share. The ex-dividend date is Monday, November 25th. This represents a $3.80 dividend on an annualized basis and a yield of 2.86%. Johnson & Johnson’s dividend payout ratio (DPR) is 46.45%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What is the G-20?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.